Lesabelimab is a monoclonal antibody targeting CD274 (PD-L1), an immune checkpoint ligand that suppresses anti-tumor immunity through interaction with the PDCD1 (PD-1) receptor; it is used in research for its potential to modulate immune responses and enhance anti-tumor activity.